Corneal Crosslinking for Treatment of Corneal Neovascularization

Launched by PRICE VISION GROUP · Mar 5, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a treatment called corneal crosslinking for people with corneal neovascularization, which is a condition where new blood vessels grow into the cornea of the eye. This can happen due to inflammation or infection and may lead to serious complications, such as corneal melting or problems with corneal transplants. The study aims to see if using a special light to activate riboflavin (a type of vitamin) can help safely treat this condition.

To join the trial, participants need to be at least 18 years old and have active inflammation or infection that is causing the blood vessels to grow in the cornea. They must also be willing to give their written consent to participate. Participants will receive treatment and be monitored for safety and effectiveness. It's important to know that pregnant or breastfeeding women cannot take part in this study, as well as anyone with certain health conditions that could affect their safety or the study's results.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
• • Signed written informed consent.
• Exclusion Criteria:
• • Known sensitivity to treatment medications
• • Current condition that in the investigator's opinion could compromise safety or data integrity.
• • Pregnancy (including plan to become pregnant) or lactation during the course of the study